home / stock / phio / phio news

PHIO News and Press, Phio Pharmaceuticals Corp. From 04/03/25

Stock Information
Company Name: Phio Pharmaceuticals Corp.
Stock Symbol: PHIO
Market: NASDAQ
Website: phiopharma.com
Menu
PHIO PHIO Quote PHIO Short PHIO News PHIO Articles PHIO Message Board
Get PHIO Alerts

News, Short Squeeze, Breakout and More Instantly...
PHIO - Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary I...
PHIO - Phio Pharmaceuticals GAAP EPS of -$9.08 misses by $0.54

2025-03-31 17:08:36 ET More on Phio Pharmaceuticals Phio Pharmaceuticals sharply lower on equity offering Seeking Alpha’s Quant Rating on Phio Pharmaceuticals Historical earnings data for Phio Pharmaceuticals Financial information for Phio Pharmaceutic...

PHIO - Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-762 3 rd Cohort now fully enrolled in on-going clinical study Marlborough, Massachusetts--(Newsfile Corp. - March 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology compa...

PHIO - American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session Marlborough, Massachusetts--(Newsfile Corp. - March 10, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASY...
PHIO - Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Marlborough, Massachusetts--(Newsfile Corp. - March 5, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in killin...

PHIO - Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL ® siRNA gene silencing technology designed to make the body's immune cells more effective in ki...

PHIO - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - February 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its IN...
PHIO - Phio Pharmaceuticals files to sell 5.93M shares of common stock for holders

2025-01-21 16:45:02 ET More on Phio Pharmaceuticals Phio Pharmaceuticals sharply lower on equity offering Financial information for Phio Pharmaceuticals Read the full article on Seeking Alpha For further details see: Phio Pharmaceuticals files to sell 5.9...

PHIO - Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Raised approximately $12.08 million in gross proceeds since beginning of December 2024 Proceeds intended to be directed for development costs to be incurred in connection with PH-762 clinical activities Marlborough, Massachusetts--(Newsfile Corp. - January 21, 2025) - Phio Pharmaceutical...

PHIO - Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - January 16, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing cancer c...
Previous 10 Next 10